Industrial Exhibition

1) Industrial Workshops

Technical Workshop I

Illumina
Genome-Wide Massively Parallel Sequencing of Formaldehyde Fixed-Paraffin Embedded (FFPE) Tumor Tissues for Copy-Number- and Mutation-Analysis

Dr. Michal-Ruth Schweiger, Max Planck Institute for Molecular Genetics, Berlin, Germany

Formalin-fixed and paraffin embedded (FFPE) tissue samples are amply available from surgical tumor resections and histopathological diagnosis, and comprise tissue from precursor lesions, primary tumors, lymphogenic and/or hematogenic metastases.
The application of second generation sequencing techniques on small amounts of paraffin (FFPE) embedded pathological material will be presented. In addition, several targeted re-sequencing approaches will be explained and their power demonstrated on selected cancer-related projects. The combination of targeted re-sequencing approaches and NGS of FFPE tissues opens up the possibility to analyze tissue samples which have been collected during routine clinical work as well as in the context of clinical trials. Large-scale studies using this tissue material will result in a better prediction of the prognosis of cancer patients and the early identification of patients which will respond to therapy.

Wednesday, 3rd March 2010
3.00pm – 4.30pm
Room B

Technical Workshop II

PerkinElmer
New technologies in prenatal application: Array CGH & BACs-on-BeadsTM

Dr. Markus Stumm, Zentrum für Pränataldiagnostik, Berlin, Germany
Dr. med. Isabel Filges and/or Prof. Peter Miny, UkBB, Basel; Switzerland
Dr. Francesca Grati, Toma Lab, Milan, Italy

Wednesday, 3rd March 2010
3.00pm – 4.30pm
Room M

Technical Workshop III

Roche Diagnostics GmbH
Real Time PCR based Nucleic Acid Analysis in Human Genetics

Genotyping Possibilities with Quantitative PCR
Dr. Dierk Evers, Roche Diagnostics GmbH, Mannheim, Germany

Nach Abschluss der Sequenzierung des humanen Genoms konzentrieren sich viele Labore jetzt auf die Millionen winzigster Unterschiede zwischen Individuen, die Wirkstofftoleranz, Anfälligkeit für viele Krankheiten und anderes beeinflussen. Dafür sind neue Strategien und Methoden erforderlich und in der Praxis der Mutationsdetektion werden Aspekte des Hochdruchsatz und der Konsteneffizienz immer wichtiger.
The sequencing of the human genome being completed, many labs now concentrate on looking for millions of minute differences between individuals accounting among others for drug tolerance and susceptibility to many diseases. New strategies and methods are required, and high throughput aspects and cost effectiveness are becoming increasingly important for practical mutation detection.

mRNA and ChIPed-DNA profiling using high-throughput quantitative PCR
PD Dr. Silke Sperling, Max-Planck-Institut für Molekulare Genetik, Berlin, Germany

Application of the high-throughput qPCR system LightCycler® 1536 for the analysis of gene expression profiles and Protein-DNA interactions based on ChIP-DNA. Verification of sample limited data on extended cohorts provides insights into cardiac transcription networks.

Anwendung des Hochdurchsatz-qPCR-Systems LightCycler® 1536 für die Analyse von Genexpressionsprofilen und Protein-DNA-Interaktionen auf der Basis von ChIP-DNA. Verifikation begrenzter Probendaten auf erweiterten Kohorten ergibt neue Erkenntnisse über Transkriptionsnetzwerke im Herzen.

Wednesday, 3rd March 2010
3.00pm – 4.30pm
Room C

Technical Workshop IV

Cartagenia
Routine clinical interpretation of copy number variation

Peter N. Robinson, Computational Biology Group, Universitätsklinikum Charité, Humboldt-Universität Berlin Germany
The use of structured phenotype ontologies in differential diagnosis.

Hartmut Engels, Institut für Humangenetik, Universitätsklinikum Bonn, Germany
Clinical CNV processing of large volumes of SNP-array data: experiences.

Steven Van Vooren, Cartagenia, Leuven Belgium
The BENCH database and software: supporting routine clinical interpretation of copy number variation.

Routine use of Array-CGH in clinical practice brings challenges in interpretation: how do we make clinical decisions with confidence in a context where genetic knowledge is changing and growing? How can we build a uniform diagnostic work-flow and have trust in the clinical decisions we make? How can we identify those genetic findings from our experiments that are relevant in the context of a patient's clinical image? In short, how can we diagnose uniformly and confidently in this complex and evolving setting? During this satellite symposium, sponsored by Cartagenia, speakers with clinical experience will take the floor and will focus on these issues: how to attain fast and accurate interpretation of copy number variation in a routine clinical context, how to resolve the bottlenecks in information management that come with routine analysis of array-CGH data, and how to leverage patients' accurate structured phenotype descriptions to support
differential diagnosis.

Thursday , 4th March 2010
11.15am – 12.30am
Room B

Technical Workshop V

Roche Diagnostics GmbH
Recent Applications of 454 High Throughput Sequencing in Human Genetics

Resequencing of the human genome using 454 sequencing systems

Dr. Marcus Droege, Roche Diagnostics GmbH, Penzberg, Germany

Die Präsentation stellt die beiden Sequenziersysteme der 454-Sequenziertechnologie, den GS FLX sowie den GS Junior, vor und zielt auf Applikationen im Bereich der humanen Resequenzierung ab. Es wird gezeigt, dass unter Verwendung der 454-Technologie mit ihrer langen Leseweite das kompletteste Bild über genomische Variationen, von SNPs über Insertionen und Deletionen, bis hin zu größeren strukturellen Variationen aufgezeichnet werden kann.

The presentation will provide a short overview about the two 454 systems, the GS FLX and the GS Junior, a newly developed bench top system, and will focus on applications in the field of human resequencing. It will be demonstrated that the 454 sequencing technology with its long read length provides the most complete picture on human genome variations, from SNPs, over insertions and deletion to larger structural variations.

SeqCap and the detection of balanced chromosomal aberrations

Dr. Alexander Kohlmann, MLL Münchner Leukämielabor GmbH, München, Germany

Leukämiediagnostik beruht nach dem heutigen Stand der Technik auf einer Vielzahl von komplexen Labormethoden. Next-Generation Sequencing hat das Potential schon bald derzeitige Methoden zu ergänzen bzw. teilweise sogar abzulösen. 454-Sequenzierungsverfahren versprechen sowohl eine hochauflösende Charakterisierung eines Krebsgenoms als auch die sehr sensitive Detektion von molekularen Mutationen.

The genetic and molecular characterization necessary for optimal treatment of acute myeloid leukemia (AML) requires a combination of different labor-intensive methods. Here, we combined a targeted DNA sequence enrichment assay with 454 PicoTiterPlate pyrosequencing to evaluate whether this technique allows a comprehensive genetic characterization in a one-step procedure.

Thursday , 4th March 2010
11.15am – 12.30am
Room C

Technical Workshop VI

Agilent Technologies
Using high-resolution CGH arrays for studying genetic disorders: recent developments and examples of clinical studies

Thursday , 4th March 2010
11.45am – 1.00pm
Room M

2) List of industrial exhibitors

(15.01.2010)
Exhibiton number / companies

• W05 Abbott Molecular
• O10 Affymetrix
• W11 Agilent Technologies
• W01 Applied Spectral Imaging GmbH / Visitron Systems GmbH
• O11 ATLAS Biolabs
• O17 Beckman Coulter GmbH
• O12 BIOGLOBE
• W06 Bioline GmbH
• O14 Biozym Scientific GmbH
• O15 BLUEGNOME
• W02 CARTAGENIA
• W04 DNA Genotek
• W14 febit biomed gmbh
• W09 FINE SCIENCE TOOLS GMBH
• W08 GATC Biotech AG
• O05 ILLUMINA
• O08 imaGenes GmbH
• W07 Integrated DNA Technologies
• W10 IPSOGEN
• W03 JSI medical systems GmbH
• O13 KREATECH DIAGNOSTICS
• O09 Luminex
• O02 METASYSTEMS / CARL ZEISS MICROIMAGING
• O03 New England BioLabs GmbH
• W13 Orphanet Deutschland
• O16 Oxford Gene Technology
• O01 PerkinElmer
• O06 qiagen
• W12 Roche Diagnostics GmbH
• O04 Sarstedt AG & Co.
• O07 SERVA Electrophoresis GmbH
  
  
  W = Westflügel / West Wing
  O = Ostflügel / East Wing
  

Our trade exhibition organiser

Congress Partner GmbH

Stefanie Hetter
(Exhibition and Sponsoring Management)
stefanie.hetter@mci-group.com

MCI - Berlin Office
Congress Partner GmbH
Markgrafenstr. 56
D – 10117 Berlin

Phone +49 (0)30 20 459 - 58
Fax +49 (0)30 20 459 - 50
www.mci-group.com